Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact of response on survival differed by the ICI type. We conducted a study on 137 patients who received ICIs (pembrolizumab or atezolizumab) plus chemotherapy for chemotherapy-naïve advanced NSCLC. We analyzed the association between response and survival for each type of ICIs. In the response group, the pembrolizumab-based regimen had significantly more prolonged PFS than the atezolizumab-based regimen (48.1 vs. 8.6 months, P治疗应答是用于评估癌症化疗疗效的生存替代标志物。然而目前尚不明确，治疗应答对生存的影响是否因免疫检查点抑制剂（Immune Checkpoint Inhibitor, ICI）的类型而异。本研究旨在评估治疗应答对生存的影响是否因ICI类型不同而存在差异。本研究纳入137例初治晚期非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）患者，所有患者均接受ICI（帕博利珠单抗或阿替利珠单抗）联合化疗的治疗方案。我们针对不同类型的ICI，分别分析了治疗应答与生存之间的关联。在治疗应答人群中，基于帕博利珠单抗的治疗方案较基于阿替利珠单抗的方案可显著延长无进展生存期（Progression-Free Survival, PFS）（48.1个月 vs 8.6个月，P